56. Fessel, J. (2024). All GLP-1 agonists should, theoretically, cure alzheimer’s dementia but dulaglutide might be more effective than the others. Journal of Clinical Medicine, 13(13), 3729. https://doi.org/10.3390/jcm13133729. 57. Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H.A.M. (2022). GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells, 11(13):2023. doi: 10.3390/cells11132023. 58. Novo Nordisk. (2024). Semaglutide in early Alzheimer’s: EVOKE and EVOKE+ clinical trials. https://clinicaltrials.gov/study/NCT04777396. 59. BioSpace. (2024, 20 November). GLP-1 Receptor Agonist Market worth $55.70 Billion by 2031, Coherent Market Insights [Press release].https://www.biospace.com/press-releases/glp-1-receptor-agonist-market-worth-55-70-billion-by-2031- coherent-market-insights. 60. Kopp, K.O., Glotfelty, E.J., Li, Y., & Greig, N.H. (2022). Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research, 186, 106550. https://doi.org/10.1016/j.phrs.2022.106550. 61. Pyka, P ., Garbo, S., Fioravanti, R., Jacob, C., et al. (2024). Selenium-containing compounds: A new hope for innovative treatments in alzheimer’s disease and parkinson’s disease. Drug Discovery Today, 29(8), 104062. https://doi.org/10.1016/j.drudis.2024.104062. 62. Lobo, A. (2024, 17 September). In parkinson’s disease, healthcare expenses among largest part of cost. Parkinson’s News Today. https://parkinsonsnewstoday.com/news/parkinsons-disease-healthcare-expenses-largest-part-cost/. 63. Mayo Foundation for Medical Education and Research. (2024, 8 November). Alzheimer’s disease. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447. 64. U.S. Food and Drug Administration (FDA). (2025, 5 March). FDA clarifies policies for compounders as national GLP-1 supply begins to stabailize [Press release]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies- compounders-national-glp-1-supply-begins-stabilize. 65. Don Tracy, A.E. (2024, 25 June). Novo Nordisk to invest $4.1 billion in expanding manufacturing capabilities in the United States. PharmExec. https://www.pharmexec.com/view/novo-nordisk-invest-4-1-billion-expanding-manufacturing- capabilities-united-states. 66. Klein, H.E. (2024, 16 May). Most insured adults still have to pay at least part of the cost of GLP-1 drugs. AJMC. https://www.ajmc.com/view/most-insured-adults-still-have-to-pay-at-least-part-of-the-cost-of-glp-1-drugs. 67. National Conference of State Legislature. (n.d.). Growth, volume, price: The skinny on GLP-1 medications - national conference of state legislatures. https://www.ncsl.org/state-legislatures-news/details/growth-volume-price-the-skinny-on- glp-1-medications. 68. Azam, S., Haque, Md. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021). The ageing brain: Molecular and cellular basis of neurodegeneration. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.683459. 69. Meissner, W.G., Remy, P ., Giordana, C., Maltête, et al. (2024). Trial of lixisenatide in early parkinson’s disease. New England Journal of Medicine, 390(13), pp. 1176-1185. https://doi.org/10.1056/nejmoa2312323. 70. BioSpace. (2024, 9 December). Evidence mounts for potential of glp-1s in alzheimer’s disease. https://www.biospace.com/drug-development/evidence-mounts-for-potential-of-glp-1s-in-alzheimers-disease. 71. Dubai Future Foundation (DFF). (2024, 11 February) Navigating 10 megatrends shaping our future in 2024. https://www.dubaifuture.ae/navigating-10-megatrends-shaping-our-future-in-2024. 72. Maity, D., Guha Ray, P ., Buchmann, P ., Mansouri, M., & Fussenegger, M. (2023). Blood-glucose-powered metabolic fuel cell for self-sufficient bioelectronics. Advanced Materials, 35(21). https://doi.org/10.1002/adma.202300890. 73. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2024, 28 December). Continuous glucose monitoring. https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/continuous-glucose-monitoring. 74. Zargartalebi, H., Mirzaie, S., GhavamiNejad, A., Ahmed, S. U., et al. (2024). Active-reset protein sensors enable continuous in vivo monitoring of inflammation. Science, 386(6726), pp. 1146-1153. https://doi.org/10.1126/science.adn2600. 75. Florea, L., & Diamond, D. (2022). Sensors and “The internet of biochemical things”. Frontiers in Sensors, 3. https://doi.org/10.3389/fsens.2022.1010212. 76. Huang, C.-W., Lin, C., Nguyen, M.K., Hussain, A., et al. (2023). A review of Biosensor for environmental monitoring: Principle, application, and corresponding achievement of Sustainable Development Goals. Bioengineered, 14(1), pp. 58-80. https://doi.org/10.1080/21655979.2022.2095089. 77. Albu, C., Chira, A., Radu, G.-L., & Eremia, S.A. (2025). Advances in cost-effective chemosensors for sustainable monitoring in food safety and processing. Chemosensors, 13(3), 113. https://doi.org/10.3390/chemosensors13030113. 78. Institute of Medicine and National Research Council Committee to Ensure Safe Food from Production to Consumption. (1998). The Changing Nature of Food Hazards: Cause for Increasing Concern in Ensuring Safe Food: From Production to Consumption. https://www.ncbi.nlm.nih.gov/books/NBK209107/. 79. Lino, C., Barrias, S., Chaves, R., Adega, F. et al. (2022). Biosensors as diagnostic tools in clinical applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1877(3), 188726. https://doi.org/10.1016/j.bbcan.2022.188726. 80. Florea, L., & Diamond, D. (2022). Sensors and “The internet of biochemical things”. Frontiers in Sensors, 3. https://doi.org/10.3389/fsens.2022.1010212. 81. Essington, E. A., Vezeau, G. E., Cetnar, D. P ., Grandinette, E. (2024). An autonomous microbial sensor enables long-term detection of TNT explosive in natural soil. Nature Communications, 15, 10471. https://doi.org/10.1101/2024.10.08.617249. Top 10 Emerging Technologies of 2025 45